U.S. Women's Health - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, the u.S. women's health market size is expected to increase from USD 72.86 billion in 2025 to USD 76.21 billion in 2026 and reach USD 92.42 billion by 2031, growing at a CAGR of 4.60% over 2026-2031.

This report is Segmented by Offering (Pharmaceuticals, Devices, Diagnostics, Digital Health, Nutraceuticals), Application (Contraception, Fertility, Menopause, and More), Care Setting (Hospitals, OB-GYN, Fertility, Labs, Telehealth), Age Group (Adolescents, Reproductive, Peri-, Postmenopausal), Distribution (Retail, Online, Specialty, Hospital, DTC). The Market Forecasts are Provided in Terms of Value (USD).

U.S. Women's Health Market Trends and Insights

Rising Demand for Noninvasive and In-Office Women's Health Procedures

The United States women's health market is increasingly adopting procedures in lower-acuity settings. In April 2026, Femasys introduced FemaSeed Complete, enabling OB-GYNs to perform first-line inseminations and in-office sperm preparations, reducing reliance on external labs. This innovation simplifies fertility care access and lowers patient costs. Additionally, the approval of a new Category III CPT code for FemaSeed intratubal insemination in early 2026 strengthens reimbursement pathways, accelerating treatment adoption and patient participation.

Expanding Clinical Recognition of Menopause as a Treatable Condition

Menopause care is becoming a mainstream focus in the United States women's health market, driving increased demand. The FDA approved elinzanetant in October 2025, expanding non-hormonal treatment options for menopause-related hot flashes. In February 2026, the FDA removed boxed warnings from six hormone therapy products, addressing long-standing prescribing concerns. These developments are fostering evidence-based care and encouraging more women to seek diagnosis and treatment during midlife.

Persistent Underdiagnosis and Late Treatment Initiation

Underdiagnosis limits the United States women's health market from converting clinical needs into treatment volumes. Polycystic ovary syndrome affects 6% to 12% of women of reproductive age, yet many remain undiagnosed for extended periods. Endometriosis in the United States faces an average diagnostic delay of 4.4 years, leading to economic burdens as care often begins after symptoms worsen. Uterine fibroids and endometriosis remain underdiagnosed across care settings, creating a gap between prevalence and documented treatment. Late diagnoses reduce early-stage pharmaceutical use and shift patients toward complex, less scalable interventions.

Other drivers and restraints analyzed in the detailed report include:

1. Higher Utilization of Fertility Diagnostics and Assisted Reproductive Technologies
2. Payor and Employer Interest in Women's Health Benefits
3. Coverage Friction for Long-Acting Contraception and Fertility Treatments

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

In 2025, pharmaceuticals accounted for 45.12% of the United States women's health market, driven by their role in managing contraception, menopause, endometriosis, and PCOS. Prescription therapies remain the primary treatment for high-volume conditions. The FDA's approval of elinzanetant in October 2025 expanded non-hormonal menopause treatment options. Organon reported a 16% decline in women's health revenue in Q1 2026, emphasizing the need for portfolio renewal alongside scale.

Digital health solutions are projected to grow at a 7.25% CAGR through 2031, making them the fastest-growing segment. Maven expanded its virtual clinic in May 2026, integrating GLP-1 care, hormone therapy, and over 30 women's health specialties. Diagnostics and device-led offerings, such as the Onclarity HPV Self-Collection Kit and BD Onclarity HPV Assay, are enhancing access to less invasive care pathways.

Contraception and family planning represented 36.76% of the United States women's health market in 2025, reflecting their broad role across retail, provider, and public coverage channels. This segment benefits from recurring prescriptions, long-acting products, and preventive care, supported by digital platforms for consultations and renewals.

Menopause management is projected to grow at a 6.56% CAGR through 2031, driven by new non-hormonal treatments and updated hormone therapy labels. Endometriosis and PCOS remain key growth areas due to high disease burden and unmet needs, with diagnosis improvements expected to boost medication use and specialist referrals.

Complete Report Scope:

• By Offering
  • Pharmaceuticals
  • Medical Devices
  • Diagnostics
  • Digital Health Solutions
  • Nutraceuticals and Wellness Products
• By Application
  • Contraception and Family Planning
  • Fertility and Reproductive Endocrinology
  • Menopause Management
  • Osteoporosis Prevention and Treatment in Women
  • Endometriosis and Uterine Fibroids
  • PCOS Management
  • Breast Health and Screening-Linked Care
• By Care Setting
  • Hospitals
  • OB-GYN Clinics
  • Fertility Centers
  • Diagnostic Laboratories
  • Retail and Mail-Order Pharmacies
  • Telehealth and Virtual Women's Health Platforms
• By Age Group
  • Adolescents and Young Adults
  • Reproductive Age Women
  • Perimenopausal Women
  • Postmenopausal Women
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Specialty Pharmacies
  • Direct-to-Consumer and Employer Channels

List of Companies Covered in this Report:

1. Abbvie
2. Amgen
3. Ascend Wellness Holdings, Inc.
4. Bayer
5. Dare Bioscience, Inc.
6. Exact Sciences
7. Femasys Inc.
8. Hologic
9. Insulet
10. Johnson & Johnson
11. Labcorp Holdings Inc.
12. Merck
13. Myovant Sciences Ltd.
14. Organon
15. Pfizer
16. Progyny, Inc.
17. Quest Diagnostics
18. Teva Pharmaceutical Industries
19. The Cooper Companies
20. Thermo Fisher Scientific

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support